Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

1-25 of 122 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

13-year survival oligometastatic Merkel cell carcinoma: a case report.
Trampetti I, Faivre JC, Geoffrois L, Gehin W, Renard S
J Med Case Rep, 18(1):455, 18 Sep 2024
Cited by: 0 articles | PMID: 39289742 | PMCID: PMC11409691
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.
Groeneveld CS, Pfister C, Culine S, Harter V, Krucker C, Fontugne J, Dixon V, Sirab N, Bernard-Pierrot I, de Reyniès A, Radvanyi F, Allory Y, VESPER trial investigators
Ann Oncol, S0923-7534(24)04016-X, 17 Sep 2024
Cited by: 0 articles | PMID: 39299443
Add to export list
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.
Fizazi K, Le Teuff G, Fléchon A, Pagliaro L, Mardiak J, Geoffrois L, Laguerre B, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Cancel M, Juzyna B, Reckova M, Naoun N, Logothetis C, Culine S
J Clin Oncol, 42(28):3270-3276, 21 Aug 2024
Cited by: 2 articles | PMID: 39167741
Add to export list
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, [...] LITESPARK-005 Investigators
N Engl J Med, 391(8):710-721, 01 Aug 2024
Cited by: 1 article | PMID: 39167807
Add to export list
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
Guigay J, Le Caer H, Ferrand FR, Geoffrois L, Saada-Bouzid E, Fayette J, Sire C, Cupissol D, Blot E, Guillet P, Pavillet J, Bozec L, Capitain O, Rolland F, Debourdeau P, Pointreau Y, Falandry C, Lopez S, Coutte A, [...] and GORTEC
Lancet Healthy Longev, 5(6):e392-e405, 14 May 2024
Cited by: 0 articles | PMID: 38759667
Add to export list
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, [...] KEYNOTE-412 Investigators
Lancet Oncol, 25(5):572-587, 29 Mar 2024
Cited by: 8 articles | PMID: 38561010
Add to export list
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, Gravis G, Thibault C, Laguerre B, Barthelemy P, Borchiellini D, Gross-Goupil M, Geoffrois L, Rolland F, Thiery-Vuillemin A, Tantot F, Chaput N, Naigeon M, Teixeira M, [...] Albiges L
Eur J Cancer, 201:113589, 03 Feb 2024
Cited by: 0 articles | PMID: 38382153
Add to export list
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S, VESPER Trial Investigators
Lancet Oncol, 25(2):255-264, 21 Dec 2023
Cited by: 8 articles | PMID: 38142702
Add to export list
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity.
Marret G, Temam S, Kamal M, Even C, Delord JP, Hoffmann C, Dolivet G, Malard O, Fayette J, Capitain O, Vergez S, Geoffrois L, Rolland F, Zrounba P, Laccourreye L, Saada-Bouzid E, Aide N, Bénavent V, Klijianenko J, [...] Le Tourneau C
Sci Rep, 13(1):22524, 18 Dec 2023
Cited by: 2 articles | PMID: 38110561 | PMCID: PMC10728082
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
de Vries-Brilland M, Rioux-Leclercq N, Meylan M, Dauvé J, Passot C, Spirina-Menand E, Flippot R, Fromont G, Gravis G, Geoffrois L, Chevreau C, Rolland F, Blanc E, Lefort F, Ravaud A, Gross-Goupil M, Escudier B, Negrier S, Albiges L
J Immunother Cancer, 11(11):e006885, 01 Nov 2023
Cited by: 3 articles | PMID: 37935564 | PMCID: PMC10649801
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Billon E, Dalban C, Oudard S, Chevreau C, Laguerre B, Barthélémy P, Borchiellini D, Geoffrois L, Negrier S, Joly F, Thiery-Vuillemin A, Gross-Goupil M, Rolland F, Priou F, Mahammedi H, Tantot F, Escudier B, Chabaud S, Albiges L, Gravis G
Eur Urol Oncol, 7(4):742-750, 07 Oct 2023
Cited by: 0 articles | PMID: 37813745
Add to export list
Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacy
Marret G, Temam S, Kamal M, Even C, Delord J, Hoffmann C, Dolivet G, Malard O, Fayette J, Capitain O, Vergez S, Geoffrois L, Rolland F, Zrounba P, Laccourreye L, Saada-Bouzid E, Aide N, Bénavent V, Klijianienko J, [...] Tourneau CL
Research Square, 25 Aug 2023
Cited by: 0 articles | PPR: PPR709002
Add to export list Preprint v1
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
Baudry E, Naoun N, Auclin E, Saldana C, Barthelemy P, Geoffrois L, Thibault C, de Vries-Brilland M, Borchiellini D, Maillet D, Hirsch L, Vauchier C, Carril-Ajuria L, Colomba E, Bernard-Tessier A, Escudier B, Flippot R, Albigès L
Eur J Cancer, 193:113292, 18 Aug 2023
Cited by: 1 article | PMID: 37717282
Add to export list
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, [...] Rosenberg JE
J Clin Oncol, 41(25):4107-4117, 27 Jun 2023
Cited by: 44 articles | PMID: 37369081 | PMCID: PMC10852367
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.
Geoffrois L, Harlé A, Sahki N, Sikanja A, Granel-Brocard F, Hervieu A, Mortier L, Jeudy G, Michel C, Nardin C, Huin-Schohn C, Merlin JL
BMC Cancer, 23(1):554, 16 Jun 2023
Cited by: 1 article | PMID: 37328818 | PMCID: PMC10273694
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ, COSMIC-313 Investigators
N Engl J Med, 388(19):1767-1778, 01 May 2023
Cited by: 43 articles | PMID: 37163623 | PMCID: PMC10257898
Add to export list Free full text in Europe PMC
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, [...] Thibault C
Eur J Cancer, 182:66-76, 13 Jan 2023
Cited by: 4 articles | PMID: 36746010
Add to export list
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, [...] Bourhis J
Eur J Cancer, 183:24-37, 09 Jan 2023
Cited by: 10 articles | PMID: 36796234
Add to export list
La pandémie COVID-19 est associée à des mélanomes diagnostiqués à un stade plus avancé
Skowron F, Mouret S, Seigneurin A, Montaudié H, Maubec E, Grange F, Quéreux G, Celerier P, Adle A, Dalac S, De Quatrebarbes J, Zehou O, Safia A, Muller P, Modiano P, Misery L, Litrowski N, Brunet Possenti F, Mortier L, [...] Leccia M
Annales de Dermatologie et de Vénéréologie - FMC, 2(8):A131-A131, 01 Nov 2022
Cited by: 0 articles | PMCID: PMC9748166
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Loriot Y, Texier M, Culine S, Fléchon A, Thiery-Vuillemin A, Gravis G, Geoffrois L, Chevreau C, Gross-Goupil M, Barthelemy P, Bompas E, Mahammedi H, Laguerre B, Lacourtoisie SA, Helissey C, Ladoire S, Abraham C, Massard C, Grimaldi S, Fizazi K
Eur Urol, 82(2):172-179, 20 May 2022
Cited by: 6 articles | PMID: 35599187
Add to export list
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L
Clin Genitourin Cancer, 20(5):488-494, 10 Jul 2022
Cited by: 5 articles | PMID: 35977881
Add to export list
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.
Saint-Ghislain M, Derrien AC, Geoffrois L, Gastaud L, Lesimple T, Negrier S, Penel N, Kurtz JE, Le Corre Y, Dutriaux C, Gardrat S, Barnhill R, Matet A, Cassoux N, Houy A, Ramtohul T, Servois V, Mariani P, Piperno-Neumann S, [...] Rodrigues M
Eur J Cancer, 173:105-112, 19 Jul 2022
Cited by: 9 articles | PMID: 35863105
Add to export list
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G, Thiery-Vuillemin A, Albigès L, Walz J, Lang H, Balssa L, Parier B, Geoffrois L, Bensalah K, Schlürmann F, Ladoire S, Bigot P, Borchiellini D, Cassuto O, Thibault C, Ingels A, Saldana V, Roubaud G, Bernhard JC, [...] Barthélémy P
Eur Urol Oncol, 5(5):577-584, 17 Jul 2022
Cited by: 12 articles | PMID: 35853818
Add to export list
Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.
Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Burgy M, Schuster C, Malouf G, Fritsch A, Lang H, Tricard T, Borchiellini D, Geoffrois L, Barthelemy P
Support Care Cancer, 30(8):6583-6591, 29 Apr 2022
Cited by: 0 articles | PMID: 35484315
Add to export list
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S, Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, Geoffrois L, Fiore FD, Roubaud G, Barthélémy P, Voog E, Emambux S, Serrate C, Saldana C, Nguyen-Tan-Hon T, [...] VESPER Trial Investigators
Clin Genitourin Cancer, 19(6):554-562, 08 Sep 2021
Cited by: 5 articles | PMID: 34602349
Add to export list

1-25 of 122 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Partnerships & funding